Corcept Therapeutics (CORT) Receivables - Net (2012 - 2026)

Corcept Therapeutics has disclosed Receivables - Net across 15 years of filings, most recently posting $39.1 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $39.1 million, down 36.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.1 million (down 36.8% YoY), and the FY2025 annual result was $59.8 million, up 10.76% from the prior year.
• Receivables - Net came in at $39.1 million for Q1 2026 at Corcept Therapeutics, down from $59.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $69.6 million in Q3 2025 to a low of $27.2 million in Q1 2022.
• The 5-year median for Receivables - Net is $41.1 million (2023), against an average of $45.9 million.
• Across the five-year window, Receivables - Net surged 88.95% in 2024 and sank 36.8% in 2026, its largest moves.
• Corcept Therapeutics' Receivables - Net stood at $31.1 million in 2022, then surged by 32.41% to $41.1 million in 2023, then soared by 31.26% to $54.0 million in 2024, then advanced by 10.76% to $59.8 million in 2025, then tumbled by 34.65% to $39.1 million in 2026.
• The last three Receivables - Net figures came in at $39.1 million (Q1 2026), $59.8 million (Q4 2025), and $69.6 million (Q3 2025), per Business Quant data.